Giuliana Grossi

Vutrisiran is the first and only FDA-approved treatment that’s demonstrated reversal in neuropathy impairment with subcutaneous administration once every 3 months.

Dr. Aric Prather discusses the pandemic, his research, and his presentation from SLEEP 2022 "Sleep in the Time of COVID: An Update on How Sleep Affects the Immune System".

While there's evidence that blue light exposure can impact an individual's circadian system, Dr. Aric Prather explains that technology is only one factor of the complex issue.

Dr. Amy Licis details recent observations regarding potential underlying neurobiological reasons for sleep disturbance in pediatric patients with ADHD or autism.

Data indicate that higher levels of perceived pain related disability and greater difficulty falling asleep was associated with increased anxiety levels in adults with fibromyalgia and insomnia.

While young adults may be resistant to drinking interventions, improving sleep behavior can indirectly reduce hazardous drinking.

There are still many aspects of sleep health that need to be understood, especially in relation to the COVID-19 pandemic.

Sleep issues are prevalent among children with autism or ADHD and both these common disorders are increasing. Any provider working with children is most likely going to encounter patients struggling with sleep.

The study from SLEEP 2022 is the first to explore directionality of sleep-stress relationships in a sample of perinatal women.

Today in a late-breaking abstract from SLEEP 2022, data showed the reduction of slow wave activity in unmedicated adolescents with depression.

Dr. Aric Prather and his team at UCSF are running a large study that began in March 2021 which follows healthy individuals through the COVID-19 vaccination and booster process.

Findings suggested that actigraphy may provide additional information to self-reported sleep measures in patients with rheumatoid arthritis.

The study objective was to determine if actigraphy could serve as a complementary clinical tool for sleep evaluation in patients with rheumatoid arthritis.

The findings presented at SLEEP 2022 differ from previous studies that evaluated the objective-subjective sleep patterns of this population.

Sleep expert Aric Prather, PhD, presented a discussion at SLEEP 2022 that focused on how the immune system and sleep are related to the "ongoing and protracted" impact of the COVID-19 pandemic.

Expert Dr. Mikkael Sekeres treats patients with bone marrow diseases and in this episode he talks about treatment methods, clinical trial obstacles and the importance of reliable sources when it comes to rare conditions like MDS and AML.

Consultation aids can elevate communication around rheumatic and musculoskeletal disease, therefore promoting shared decision making between patients and clinicians.

Efanescotocog alfa is the first factor VIII therapy to be granted Breakthrough Therapy designation by the FDA.

Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

Primary care provider Dr. Gerald Smetana shares key information and resources to give PCPs all they need know about prescribing outpatient therapies for COVID-19.

The public perception of marijuana has shifted significantly, and Dr. Timothy Fong addresses how to keep up with progressive research and what risk factors still need to be better understood.

EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.

Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders.

Data from 2 studies evaluating adults with active psoriatic arthritis were announced today in preparation for EULAR 2022. The different population groups who received treatment were biologic-naive patients and TNF-inadequate responders.

Sarcoidosis expert Dr. Wonder Drake got into the field after diagnosing a patient with the disease early in her career. In this interview she explains the best way to approach a suspected case of sarcoidosis.

Dr. Carolyn Rowley talks about the Cayenne Wellness Center's mental health initiative for individuals with sickle cell disease and shares the story of one of her first patients.

In this interview, Dr. Wonder Drake shares physician resources and explains the unique presentation of sarcoidosis and how it varies by region.

Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitation center are among some of the factors associated with a new opioid use disorder diagnosis.